Soon, a 'powerful' pain reliever that could end opioid crisis

Image
ANI Washington D.C. [USA]
Last Updated : Aug 17 2017 | 11:22 AM IST

A team of scientists has discovered what they say is a powerful pain reliever that acts on a previously unknown pain pathway.

The synthetic compound, known as UKH-1114, is as effective at relieving neuropathic pain in injured mice as a drug widely used for pain relief called gabapentin, but it works at a much lower dose, with longer duration of action.

If the researchers led by chemists Stephen Martin and James Sahn at The University of Texas at Austin can demonstrate that the drug is safe, effective and nonaddictive in humans - a process that typically takes years - the discovery could be instrumental in addressing one of today's biggest public health challenges: the opioid abuse epidemic.

Alternatives to opioids have their own drawbacks, for example, gabapentin (sold as Neurontin) can cause cognitive impairment in certain individuals.

"This opens the door to having a new treatment for neuropathic pain that is not an opioid," said Martin. "And that has huge implications."

The pain drug they found binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor. Although it was discovered 25 years ago, scientists still did not know what sigma 2 did until now.

Researcher Theodore Price tested UKH-1114 on mice with nerve damage and found that it alleviated pain as well as gabapentin did, but at a much lower dose (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with 4 to 6 hours). This research is the first to demonstrate that the sigma 2 receptor may be a target for treating neuropathic pain.

The researchers have filed patent applications on the new compound.

The results are published in the journal ACS Chemical Neuroscience.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 17 2017 | 11:22 AM IST

Next Story